Ebola Bundibugyo PHEIC: second-largest outbreak ever, no approved vaccine

Summary

DRC's Ministry of Health detected an outbreak of Bundibugyo ebolavirus (Orthoebolavirus bundibugyoense) in Ituri Province; WHO declared a PHEIC on 17 May 2026. As of approximately 21 June: 1,048 confirmed DRC cases and 267 deaths; 20 Uganda cases (Kampala travellers from DRC), 2 deaths; 371 in isolation. Ituri Province accounts for 91% of DRC cases across 22 health zones; North Kivu adds 91 cases. This is the 17th Ebola outbreak in DRC and the second-largest ever globally — surpassed only by the 2014–16 West Africa Zaire outbreak. No licensed vaccine or specific treatment exists for the Bundibugyo strain; all approved Ebola medical countermeasures target Zaire ebolavirus. WHO and Africa CDC launched a joint six-month response plan targeting US$518 million; over $910 million was pledged at the 18 June Africa CDC heads-of-state briefing.

The split

The WHO-Africa CDC partnership is emphasising funding adequacy and a common response architecture. But CIDRAP and independent biosecurity assessors stress the vaccine gap as the structural difference between this outbreak and the 2018–20 DRC Zaire outbreak (where ring vaccination eventually contained it): there is simply no ring-vaccination tool for Bundibugyo. The Ituri conflict zone — hosting nearly one million displaced people — replicates the access conditions that prolonged the 2018-20 outbreak. MSF and Doctors Without Borders warn that treatment-centre shortages of medicines, ambulance fuel and staffing already constrain the response.

By the numbers

• 1,048 DRC confirmed cases, 267 deaths — as of ~21 June.
• 20 Uganda cases, 2 deaths — all Kampala travellers from DRC; no new cases since June 21.
• Ituri Province — 954 cases (91.1%) across 22 health zones; North Kivu — 91 cases.
• 17th — DRC Ebola outbreak; 2nd largest globally.
• 0 — licensed vaccines or specific treatments for Bundibugyo ebolavirus.
• $518M — six-month WHO-Africa CDC response plan target; $910M+ pledged.

Why it matters

The absence of an approved vaccine converts this from a manageable ring-vaccination problem into an outbreak-containment problem in a conflict zone — the same conditions that produced the 2018-20 extended crisis. A disease contained to DRC and Uganda for now, but with a history of cross-border spread and no prophylactic tool, is a live global PHEIC with no clear exit strategy beyond case-by-case management and experimental treatment.

What to watch

• Whether any Bundibugyo-specific vaccine or treatment enters emergency use authorisation.
• Uganda transmission chain — whether Kampala community spread develops beyond travel-linked cases.
• Whether the Ituri conflict zone remains accessible to response teams.
• Funding materialising from the $910M pledge vs. the $518M plan.